Document is current
Any future updates will be listed below
-
Authors
Stempel, Jessica M. https://orcid.org/0000-0001-9162-0579
Wang, Rong
Lee, Alfred I.
Zeidan, Amer M.
Ma, Xiaomei
Podoltsev, Nikolai A.
- License Information
-
More Information
Article History
Received: 13 December 2024
Accepted: 6 March 2025
First Online: 19 March 2025
Declarations
:
: Not applicable.
: JMS, RW, AIL, XM have no competing interests to declare that are relevant to the content of this article. N.A.P. received consultancy fees from Blueprint Medicines, Incyte, Novartis, PharmaEssentia, CTI BioPharma/Sobi, Constellation Pharmaceuticals/MorphoSys, AbbVie, Aptose Biosciences, Karyopharm, Syndax and financial support for serving on an Independent Data Review Committee for Cogent Biosciences. A.M.Z. participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Servier, Boehringer-Ingelheim, Novartis, Astellas, Daiichi Sankyo, Geron, Taiho, Seattle Genetics, Otsuka, BeyondSpring, Takeda, Ionis, Amgen, Janssen, Genentech, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, Mendus, Zentalis, Schrodinger, Regeneron, Syros, and Tyme. AMZ served on clinical trial committees for Novartis, Abbvie, Gilead, Syros, BioCryst, Abbvie, ALX Oncology, Kura, Geron and Celgene/BMS.
